A 3D‐Engineered Conformal Implant Releases DNA Nanocomplexs for Eradicating the Postsurgery Residual Glioblastoma
Citations Over TimeTop 14% of 2017 papers
Abstract
Gene therapy has great promise for glioblastoma treatment; however, it remains a great challenge to efficiently deliver genes to the brain. The incomplete resection of glioblastoma always leads to poor prognosis. Here, a 3D-engineered conformal implant for eradicating the postsurgery residual glioblastoma is designed. This implant is constructed by 3D-printing technology to match the tumor cavity and release an oncolytic virus-inspired DNA nanocomplex to kill glioblastoma cells through apoptosis induction. Meanwhile, a 3D-engineered subcutaneous glioblastoma xenograft is built to mimic the resection tumor cavity in mice. Insertion of the implant into the glioblastoma resection cavity efficiently delays tumor recurrence and significantly prolongs overall survival. This study provides a proof-of-concept of glioblastoma therapy using a conformal implant that releases oncolytic DNA nanocomplexs. This strategy can lead to the development of future precision therapy for eradicating postsurgery residual tumors.
Related Papers
- → The gamble between oncolytic virus therapy and IFN(2022)42 cited
- → Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?(2015)29 cited
- Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.(2003)
- → A138(2015)
- Oncolytic herpes simplex virus and its advances in cancer therapy(2008)